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Abstract
Intensive chemotherapy or chemotherapy plus irradiation and allogeneic stem cell transplantation 
can be curative for patients with hematologic diseases. Reduced intensity transplants can also 
achieve cure, and result in less treatment related mortality but higher relapse rates. Thus, 
optimizing the conditioning regimens used in allogeneic transplantation remains an important 
goal. We conducted a Phase I/II trial to determine the maximum tolerated dose (MTD) and dose 
limiting toxicities (DLT) of a continuous infusion of busulfan over 90 hours in conjunction with 
fludarabine followed by allogeneic related or unrelated donor transplant. Fifty-four patients with 
advanced hematologic malignancies were enrolled on this study. The MTD was identified as a 24 
hour area under the curve (AUC) of approximately 7095 uMmin which represents a 43% increase 
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over the standard total daily AUC dose of 4800 uMmin given by intermittent schedules. DLTs at 
doses over 8000 uMmin were identified as a desquamative skin rash and mucositis. No dose-
related increase in hepatic, pulmonary or other organ toxicies were seen while efficacy appeared to 
be improved at higher dose levels. Continuous infusion busulfan with intermittent fludarabine 
provides an alternative treatment strategy that is generally well tolerated and permits an increase 
in total busulfan dose with encouraging efficacy.
Introduction
The use of high dose therapy with allogeneic stem cell transplantation has been shown to be 
curative in a number of hematologic diseases. Cure rates of 30 −70% in different 
populations of patients can be identified with failure being attributed either to relapse of the 
underlying disease or treatment related mortality.1,2 In some cases, the mortality and 
morbidity associated with treatment is a result of the conditioning regimen given prior to the 
infusion of donor stem cells, whereas in other situations it is a result of the immunologic 
dysregulation that results in graft rejection, infections or graft versus host disease (GVHD) 
from infused donor immune cells. With improvement in therapeutic regimens prior to 
transplant and prevention of GVHD, better antibiotic and transfusion support, and high 
resolution human leukocyte antigen (HLA) typing, an increasing percentage of treatment 
failures are the result of relapse of underlying disease.3,4,5 This shift towards higher disease 
relapse rates has also resulted from improvements in prognostic factors, and identification of 
residual disease in patients with acute and chronic leukemia. Increasingly, patients who are 
in better risk categories are not taken to transplant, as they have a significant cure rate with 
standard therapy.6 Relapse has also become an increasingly important source of treatment 
failure in the setting of patients undergoing therapy with either reduced intensity or non-
ablative conditioning regimens, both of which rely significantly on the underlying graft-vs-
tumor effect in order to maintain remission status post-transplant.7–9
While there is data suggesting the importance of co-morbidities, age, CMV status, disease 
risk and quality of donor/recipient match in outcomes 10–12, there is also data suggesting that 
conditioning regimen intensity is important in long-term control of the underlying 
malignancy.13–16, In some diseases such as acute lymphoblastic leukemia, there is general 
agreement that better disease control is provided by the use of total-body radiation (TBI) but 
that in the majority of patients with myeloid disease, any increased benefits in disease 
control with TBI are offset by a higher likelihood of treatment related morbidity and 
mortality.17–18 Nevertheless, because of the high relapse rate in these advanced 
malignancies, there continues to be value in identifying more effective conditioning 
regimens to control the underlying disease.
Pre-clinical data by Teicher and colleagues19 have demonstrated that continuous exposure of 
malignant cells to alkylating agents in vitro provides a greater cell kill than comparable 
AUC exposure delivered by intermittent schedules. There is also clinical data that this 
approach, as demonstrated by the prolonged infusion of anthracycline in the EPOCH and 
VAD regimens, may be associated with better outcomes and improved tumor control.20–22 
Based on this work, we postulated that administering busulfan as a prolonged infusion might 
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permit a higher total AUC with reduced toxicity as a result of lower peak concentrations, 
while still providing greater disease control. In the current report we describe the results of a 
Phase I/II study report that assessed the MTD, toxicities, and clinical outcomes following 
the administration of busulfan via a prolonged infusion schedule in allogeneic transplant 
patients with advanced hematologic malignancies.
Patients and Methods
Patients with advanced, refractory, or high-risk hematologic cancers who were deemed 
suitable for myeloablative conditioning and between the ages of 20–55 were eligible for 
enrollment. All patients provided appropriate informed consent according to UNC 
Institutional Review Board policies. Patients were stratified by disease risk according to 
ASBMT/Center for International Blood & Marrow Transplant Research (CIBMTR) criteria 
(23). Co-morbidity scores were assessed using the Sorror index (10) and severity of VOD 
was assessed according to the Bearman criteria (24). Patients with other malignancies that 
did not qualify for CIBMTR stratification required demonstration of high-risk features or 
advanced disease beyond complete response (CR1) for which no other curative therapy was 
available. Acute and Chronic GVHD scoring were as outlined by Glucksberg (25) and 
Shulman (26), respectively.
Busulfan Pharmacokinetic (PK) Analysis
A test dose of .8 mg/kg adjusted ideal body weight (IBW) busulfan was administered over 
30’ followed by plasma levels at baseline, 30’, 1, 2,4, and 6 hours after start of the infusion. 
Based on the AUC and Clss values obtained with the test dose, targeted AUC dosing 
estimated to achieve the desired AUC dosing level per protocol was then undertaken.27–30 
Within one week of the test dose, patients were admitted for the therapeutic dose and 
subsequent transplant. Busulfan plasma concentrations were collected before the start of the 
90 hour infusion and then at 30’, 1, 2,4, 6, 12, 18, 24, 36, 48, 60, 72, 84, 90.5, 92 and 96 
hours following the start of the infusion. A 90-hour infusion was chosen to reflect 15/16ths 
of a full 16 dose schedule while the test dose represented 1/16th of the full 16 dose schedule. 
All whole blood samples were centrifuged at 1000 x g for 10 minutes at 4° C and aliquots of 
plasma were collected and stored at −80° C until analysis. Busulfan concentrations were 
quantified at Emory University Hospital using high-pressure gas chromatography.30 The 
lower limit of quantitation was 0.1 umol/L and the assay was linear between 0.1 and 20.0 
umol/L. AUC calculations were assessed for the test dose and on the first 6 hours of the 
therapeutic infusion, and dosages adjusted for hours 42–90 following return of the initial 
AUC values if they were more than 10% above or below the desired range.
Individual busulfan plasma concentrations were used to estimate the following PK 
parameters using a non-compartmental model on WinNonlin 4.0 (Pharsight Corp., Mountain 
View, CA): maximum plasma concentration (Cmax), area under the concentration-time 
curve through the last measurable time point (AUC); terminal half-life (t1/2), and whole 
blood clearance (Cl). The AUC was calculated using the log-linear trapezoid method. All 
AUC and clearance data was natural log-transformed and reported using descriptive 
statistics.
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In the Phase I portion of the study, patients were dosed in cohorts according to the five 
target AUC levels. Additional patients were enrolled at dose level one (standard dose) 
during the Phase I and II portions of the study if their insurance coverage did not allow 
enrollment onto a Phase I study. The maximum tolerated dose (MTD) was defined as the 
dose with the dose-limiting toxicity (DLT) rate of 0.25. A dose assignment strategy that 
allowed for delayed toxicity outcome was used.31 Initial escalation was in cohorts of three 
patients until at least one patient developed a DLT. After the initial dose escalation, patients 
were assigned to the current dose cohort if estimated DLT rate at the current dose was 
between 0.15 and 0.35. The dose was increased or decreased if the estimated DLT rate at the 
current dose was below 0.15 or higher than 0.35. The sample size for Phase I was set at 35 
patients. An additional 25 patients were enrolled to the estimated MTD. During Phase II 
portion of the trial the rate of non-relapse mortality at day 100 was monitored using the 
Pocock boundary to stop the trial if the rate was too high.32 Similarly the rate of irreversible 
Grade 3 toxicity or Grade 4 toxicity lasting more than 2 weeks was monitored. The 
acceptable rate for each was set to 0.2.
Treatment
In addition to busulfan, all patients also received daily fludarabine at a dose of 30 mg/m2/d x 
5 according to the schedule outlined in Figure 1. All patients received GVHD prophylaxis 
with tacrolimus starting on day −1 and targeted to maintain serum levels of 3–8 ug/dl. 
Patients received either alemtuzumab at a dose of 30 mg/d x 1 or 2 days depending on 
whether they were a matched related (1 day) or mismatched related or unrelated (2 days) 
donor/recipient pair. After the first 30 patients were enrolled, because of concerns over a 
high rate of viral infections, matched related patients received MTX and tacrolimus alone, or 
tacrolimus, MTX + ATG if they were mismatched related or unrelated. MTX was given at a 
dose of 5 mg/m2 on days +1, +3, and +6.33
Results
Demographics
54 patients with myeloid malignancy (36 patients), acute lymphoblastic leukemia (7 
patients), non-Hodgkin’s or Hodgkin’s lymphoma (7 patients) and a variety of 
myeloproliferative diseases or prolymphocytic leukemia (4 patients), were enrolled on this 
study (Table 1). Patients received alemtuzumab in addition to tacrolimus (30 patients), 
tacrolimus plus ATG and methotrexate (18 patients) or methotrexate and tacrolimus alone (6 
patients). 34 patients received transplants from matched unrelated donors and 20 received a 
matched related donor transplant. All recipients received peripheral blood stem cells. 
Median age of the entire patient population was 40, with 20 females and 34 males. 
Additional details of host and donor CMV status, donor/recipient sex, diagnosis, co-
morbidity index, and disease risk are listed in Table 1. Descriptions of GVHD prophylaxis, 
and the incidence of acute and chronic GVHD grade, are listed in Table 3. The data is 
presented for each of three measured Busulfan AUC doses delivered and divided into low, 
intermediate and high AUC dose cohorts.
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PK Measurements and MTD determinations
All 54 patients underwent test dose administration and PK measurements that were 
performed 4–7 days prior to initiating therapeutic dosing of busulfan. A total of 5 AUC 
levels ranging from a low dose of 4800 uMmin to a high of 8363 micromole-minutes 
(uMmin) were delivered. Dose level 3, at a targeted AUC of 6912 uMmin, was identified as 
the MTD for this regimen (Table 2). The actual average dose delivered by continuous 
infusion at dose level 3 was 7095 uMmin. Dose targeting precision was estimated by root 
mean squared error and was 10.2% for that dose. Within day and between day variability 
measured by coefficient of variation, were below 10% for all busulfan concentrations. 
Patients enrolled on each dose level were listed in Table 2 according to the targeted AUC 
administered. Fourteen patients were enrolled at dose level 1 including eleven who were 
enrolled after escalation to subsequent dose levels had occurred in order to capture PK and 
Phase II data on patients whose insurance companies precluded their participation in a Phase 
I or dose escalation study.
Toxicity and MTD
The initial dose escalations were undertaken in five separate cohorts with AUC targeted 
ranges varying from a low of 4800 uMmin to a high of 8363 uMmin delivered per 24 hours. 
Because the purpose of this trial was to define an AUC-directed dose of chemotherapy by 
continuous infusion, toxicities were determined and reported for each of these cohorts 
during the initial dose escalation portion of the trial (Table 2). Two patients on the original 
5th dose level experienced grade 4 DLT of mucositis and a desquamative, intertrigenous skin 
rash that developed between days 0 and +10. As a result, additional subjects were enrolled at 
dose level 4. When two additional DLT cases of grade 4 mucositis were identified at the 
original 4th dose level, an AUC goal of 7603 uMmin, it was determined that the 3rd dose 
level with a target AUC of 6912 uMmin and an actual AUC of 7095 uMmin was the MTD. 
Of the 24 patients treated at dose level 3, one grade 5 case of VOD was seen. No other grade 
4 or 5 regimen related toxicities were observed at this dose level.
Since AUC levels varied between the groups, and the goal was to identify an actual achieved 
AUC based dose, additional outcomes analysis were undertaken by dividing patients into 
thirds according to the actual AUCs delivered rather than the original planned AUCs (Table 
3). While we also considered AUC as a continuous covariate and estimated linear effect of 
AUC on the hazard function, the assumption that AUC affected the hazard function in a 
linear manner was incorrect and therefore we have presented results for the AUC levels 
divided into thirds. This post-hoc analysis provided larger numbers per group and allowed 
for more robust analysis and comparisons of both safety and efficacy according to the actual 
dose delivered rather than the planned dose level. With this analysis, the lowest third was 
comprised of 18 patients who received a median AUC dose of 5078 uMmin of busulfan. The 
middle third contained 18 patients who received a median dose of 6372 uMmin of busulfan 
and the highest third was comprised of 18 patients with a median AUC of 7605 uMmin. 
Grade 4 and 5 life threatening or fatal toxicities were seen in two patients in the lowest third 
who had veno-occlusive disease and severe mucositis. In the intermediate dose level, one 
patient had grade 4 mucositis and one had severe VOD, while in the highest third there was 
one fatal case of veno-occlusive disease and 2 cases of grade 4 mucositis. The individuals in 
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the highest third with grade 4 mucositis both had AUCs in excess of 8600 uMmin. 
Engraftment was as expected in all cohorts with a median time to neutral count greater than 
1000 of 13 days and platelet count greater than 20,000 without transfusion of 15 days.
Graft versus Host Disease
Thirty of the fifty-four patients were treated with alemtuzumab and 29 of them lived to day 
100 and were fully evaluable for GVHD. Of these 29 patients, 11 (38%) developed grade 2 
acute and two (7%) patients had grade 3 or 4 acute GVHD, while six (21%) patients 
developed extensive chronic GVHD and three (10%) had limited chronic GVHD (Table 3). 
Six (21%) patients had grade I GVHD and seven (24%) had no acute or chronic GVHD. 
Eighteen patients received ATG and two developed grade I acute GVHD, five (28%) 
developed grade II acute GVHD, two (11%) developed grade III acute GVHD, and three 
(17%) developed grade IV acute GVHD. Two patients developed chronic extensive GVHD. 
Four patients had no acute or chronic GVHD. Six additional patients received no ATG or 
alemtuzumab following transplantation with a matched related donor. Of these patients, two 
(33%) had grade I, two (33%) had grade II, one (17%) had grade III, and one (17%) had 
grade IV acute GVHD. One (17%) of these patients developed extensive chronic GVHD and 
none were without any GVHD.
Chimerism
Of the 54 enrolled and evaluable patients, 49 had whole blood chimerism and 46 had T cell 
chimerism measured at day 30 (Table 3). Forty-seven of 49 had ≥ 95% donor chimerism in 
the whole blood compartment and 30/45 had ≥ 95% donor chimerism in the T cell 
compartment. Of the remaining samples analyzed for whole blood chimerism, 2 were <95% 
donor (21 and 54%) and 15/45 had <95% donor T cells (range 27–94%). At day 100, 40/45 
evaluable patients had ≥ 95% donor whole blood chimerism and 25/42 had > 95% donor in 
the T cell compartment. 17/42 patients were < 95% donor T cell chimeras (range 1–91%). 
There were no differences in chimerism results as a function of either the 
immunosuppression used or busulfan dose received.
Outcomes
The purpose of this study was to identify the DLT and MTD along with identifying the 
potential value of higher doses of busulfan when administered as a prolonged IV infusion. 
Sixteen subjects had low, 20 had intermediate, and 18 had high-risk disease by CIBMTR 
criteria (Table 1). Unadjusted overall survival (OS) and relapse-free survival (RFS) for all 
54 subjects were 0.42 and 0.36 respectively. When analyzed according to the AUC low 
(group 1, 18 pts), middle (group 2, 18 pts), or high (group 3, 18 pts) dose (Table 4), OS was 
0.28, 0.39, and 0.55 and RFS was 0.22, 0.39, and 0.43, respectively (p=NS for all analyses). 
For the entire group, univariate analysis identified age, recipient CMV status, and disease 
risk as significant factors for OS and RFS (Table 3). Co-morbidity scores, diagnosis, GVH 
occurrence, donor/recipient sex and donor type (MUD or MRD) were not significant, nor 
were the non-relapse mortality rate or OS different between the three AUC groups in 
univariate analysis. The use of alemtuzumab vs ATG did not affect OS or relapse rates with 
HRs of 1.48 and 1.55 and p values of 0.27 and 0.21, respectively. Adjusted analysis by AUC 
group identified high vs low AUC dose (p=0.049) and disease risk (p=0.01) as significant 
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for both OS and RFS (Table 4, Figure 2). Outcomes were similar between AUC groups 2 
(intermediate) and 3 (high). Differences in OS and RFS were limited to the good and 
intermediate risk patients as outcomes for high-risk patients were poor for all AUC groups 
(1/18 OS and 0/18 RFS). Similar results were obtained when these analyses were performed 
according to targeted rather than measured AUC (data not shown).
Discussion
The value of allogeneic stem cell transplantation has traditionally been derived from a 
combination of the capacity of the conditioning regimen to eradicate the underlying disease, 
permit durable donor engraftment, and confer an antitumor effect (graft vs tumor) from the 
donor cell infusion. In recent years, the use of reduced intensity regimens have permitted the 
expansion of allogeneic transplants into populations of older and less robust patients and 
provide cure for a significant population that had not previously been eligible for such 
therapy. The rates of cancer relapse after RIC HCT remains unacceptably high, 
however, 1,3,4 and appear higher compared to myeloablative regimens for certain 
diseases.13,14,16 Evidence suggests that more intensive regimens are associated with 
improved disease control for those patients who are in better health and able to tolerate these 
therapies, particularly for advanced diseases such as relapsed and refractory lymphomas or 
high-risk acute myeloid and lymphoid leukemias. While retrospective data has suggested 
that the overall survivals are comparable in patients over the age of 50 treated with fully 
ablative or reduced intensity regimens, a recent trial by the Bone Marrow Transplant 
Clinical Trials Network (CTN0901) was stopped early because of an apparent increase in 
early relapse rates in the population getting less intensive therapies. Details of this study are 
not yet available, but it implies that intensive regimens continue to be valuable, particularly 
since relapse remains the major cause of treatment failure in this patient population.
In the current study, a novel approach for administration of a highly effective chemotherapy 
agent, IV busulfan, along with the immunosuppressant, fludarabine, was utilized as a means 
to allow potential dose escalation of this drug for healthy patients under the age of 55 
compared to four time a day, or once a day, administration schedules. Investigators at MD 
Anderson have identified an AUC MTD of 6000 by once daily infusion in conjunction with 
fludarabine as an appropriate dose for younger and healthier individuals. In our study, we 
were able to administer IV busulfan as a continuous infusion over 90 hours at a Phase II 
MTD of approximately 7000 uMmin AUC per 24 hours for a total AUC exposure of 26,250 
uMmin plus the test dose of approximately 1200 uMmin. This resulted in a total busulfan 
dose of approximately 27,500 uMmin and represents a 15% increase over the AUC 
identified by the MD Anderson investigators and a 43% increase over a standard AUC of 
4800 uMmin/day.17,34,35 In addition to this higher total dose of drug, the prolonged 
administration schema may result in improved cell kill as reported by Teicher and 
colleagues with preclinical testing of models using a variety of cell lines.19 While the results 
obtained in this trial do not permit conclusions regarding the anti-tumor efficacy of this 
approach, they indicate that a higher and potentially more effective dose can be administered 
safely with the continuous infusion schema described in this manuscript. It is also 
appreciated that the results at the lowest AUC may be poorer than expected, and that 
prolonged infusion may be less effective at standard doses than intermittent schedules, but 
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with small numbers and disease heterogeneity, it is not possible to provide a definitive 
analysis of these outcomes.
It is important to point out that there did not appear to be a significant increase in toxicity 
associated with these higher doses of drugs until the delivery of AUC doses above 8000 
uMmin/day at which time we identified mucositis and skin rash as the DLTs. An 
intertriginous rash associated with grade IV mucositis was seen in both patients treated at 
AUCs greater than 8000 uMmin over 24 hours, and suggests that GVHD prophylaxis 
regimens that avoid methotrexate or other mucositis enhancing agents may be useful in 
limiting this significant source of morbidity and mortality. If additional patients were 
enrolled at these levels it is likely that further organ toxicities such as hepatic or pulmonary 
damage would have been seen but it was notable that neither significant VOD of the liver 
nor interstitial pneumonitis were seen with an increased frequency at the higher dose levels. 
There was one case of severe at the lowest AUC cohort and one case at the highest dose 
level. A third case that was observed at the intermediate dose level was felt to represent 
hepatic failure in conjunction with sepsis and multi-organ failure. While early pulmonary 
complications without an identifiable infectious agent were contributors to the death of two 
subjects, whether this was from busulfan or other non-infectious causes was not discernible. 
Two long-term surviving patients have developed pulmonary complications in the presence 
of GVHD, but these were not felt to be due to busulfan. Other attendant morbidities such as 
GVHD and infectious complications were observed at a rate that is consistent with what 
would be expected using ablative regimens. There was no excess mortality associated with 
alemtuzumab, but its use was discontinued after the first 30 patients because of an 
accompanying increase in viral infections and related complications.
In summary, the use of prolonged infusion busulfan appears to allow for a higher MTD 
compared to intermittent busulfan infusion schedules. Further trials to refine and reduce the 
complications seen such as mucositis and skin rash at the highest dose levels are being 
considered along with efforts to optimize the efficacy of this approach. Other than the 
challenge of administering a continuous infusion of a drug that requires preparation 2–3 
times a day, there were no significant complications seen with this approach that were not 
also attributable to the higher doses. The use of a test dose prior to initiation of treatment 
appears to be important to identify the appropriate range for administering this drug since 
our study determined that the general accuracy of the AUC based on the busulfan clearance 
was found to be in excess of 90%. This approach holds promise as a treatment regimen that 
is tolerable and may diminish relapse rates in this population of patients with high-risk 
hematologic cancers.
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• Determination of an AUC MTD with continuous infusion busulfan in allogeneic 
transplantation
• Identification of rash and mucositis as the DLTs of high-dose continuous 
infusion busulfan
• Potential increased efficacy with an increased AUC of busulfan given as a 
continuous infusion
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treatment schema for patients enrolled on UNC LCCC 0510. Abbreviations as follows:
K Keppra: 1 g bid to start 24 hours prior to the test dose to continue through day −2 for seizure
prophylaxis.
F Fludarabine: 30 mg/m2/day x 5 days IVPB over 30 minutes on Days −7 through −3.
B Busulfan: dose by continuous IV infusion over 90 hours on Days −7 to −4. Pts will receive a
single dose of busulfan at 0.8 mg/kg over 2 hours between days –15 and −10 followed by
the targeted 90 hour infusion on Days –7 to −4 as described in section 3.2.2.
ATG Rabbit anti-thymocyte globulin: .5 mg/kg on day −3 and 2.5 mg/kg on day −2 (group 2
only)
A Thirty patients received alemtuzumab at a dose of 30 mg/d x 1 or 2 days depending on
whether they were a matched related (1 day) or mismatched related or unrelated (2
days) donor/recipient pair
M Methotrexate: 5 mg/m2 on days +1, +3, and +6.
T Tacrolimus: Tacrolimus target serum levels are 3–8 ng/mL. The suggested starting dose
was 0.03 mg/kg PO BID from Day – 1 to Day +120 and then taper by Day +180
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Kaplan Meier curves by : Top, OS; Bottom, RFS.
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Table 1
Demographics by Measured Busulfan AUC Dose









# patients 54 18 18 18
M/F 20 F, 34 M 9 F, 9 M 3 F, 15 M 8 F, 10 M
Age (median) 40 37 40 45
Host CMV status 18 Neg, 36 Pos 8 Neg, 10 Pos 4 Neg, 14 Pos 6 Neg, 12 Pos

















AML/MDS/CML 26/8/1 5/5/0 9/2/0 12/1/1
    - ALL 7 6 1 0
    - NHL/HD 5/2 0/0 3/2 2/0
    - MF/CLL/CMML 1/1/1 0/1/0 0/0/1 1/0/0
    - PCL 2 1 0 1
Type of transplant
    - MUD 34 11 10 13
    - MRD 20 7 8 5
CMI (median) 2 1 2 2
Disease risk
    - Low 16 8 4 4
    - Intermediate 20 5 7 8
    - High 18 5 7 6
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Table 3
Toxicities and Outcomes by Measured AUC





















18 (33%) 6 (33%) 6 (33%) 6 (33%)
GVHD prophylaxis:
Tacrolimus +
Alemtuzumab 30 15 10 5
ATG + MTX 18 3 6 9
MTX 6 0 2 4
Acute GVHD grade ≥ 2 28 (52%) 7 (39%) 10 (56%) 11 (61%)
Acute GVHD grade 3,4 9 (17%) 2 (11%) 4 (22%) 3 (17%)
Chronic GVH;
Intermediate/Severe
12 (22%) 4 (22%) 6 (33%) 2 (11%)
OS at 3 year 0.42 0.28 0.39 0.55
RFS at 3 year 0.36 0.22 0.39 0.43
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